The metabolic syndrome is associated with increased risk of diabetes and coronary heart disease. Although higher BMI and other related factors have been frequently associated with colorectal cancer, whether the metabolic syndrome is associated with the risk of colorectal cancer is unclear. We therefore assessed the association of the metabolic syndrome with the risk of colorectal cancer in a subsample of participants of the Women's Health Initiative who had repeated measurements of the components of the syndrome at baseline and during follow-up. Women with diabetes at baseline enrollment were excluded. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI) at baseline and in time-dependent analyses. Among 4862 eligible women, 81 incident cases of colorectal cancer were identified over a median follow-up of 12 years. Presence of the metabolic syndrome at baseline was associated with increased risk of colorectal cancer (HR 2.15, 95% CI 1.30-3.53) and colon cancer (HR 2.28, 95% CI 1.31-3.98). These associations were largely explained by positive associations of serum glucose and systolic blood pressure with both outcomes. Time-dependent covariate analyses supported the baseline findings. Our results suggest that the positive association of the metabolic syndrome with risk of colorectal cancer is largely accounted for by serum glucose levels and systolic blood pressure. The biological mechanism underlying these associations remains to be clarified.
Introduction
Obesity, visceral adiposity, and physical inactivity show consistent positive associations with risk of colorectal cancer (Moghaddam et al., 2007; Huxley et al., 2009; Ning et al., 2010) . These factors are the major modifiable determinants of insulin resistance, hyperinsulinemia, hyperglycemia, and the metabolic syndrome, (McKeown-Eyssen, 1994; Giovannucci, 1995; Giovannucci, 2007) a cluster of anthropometric and clinical factors (elevated abdominal adiposity, blood glucose, triglycerides, and blood pressure, and low levels of HDL-cholesterol). The metabolic syndrome has been demonstrated to predict risk of developing type 2 diabetes and cardiovascular disease (Ford et al., 2002; Meigs, 2003) . In the USA, both obesity and the metabolic syndrome have increased in prevalence in recent years, and it is estimated that currently, 50 million Americans have the metabolic syndrome (Sathyaprakash and Henry, 2002; Alexander et al., 2003) .
Hyperinsulinemia and hyperglycemia result from a dysregulation of the balance between insulin secretion and insulin action and are precursors of type-2 diabetes. Insulin has long been regarded as a possible mediator of the effects of obesity and physical activity on colorectal cancer risk (McKeown-Eyssen, 1994; Giovannucci, 1995) . Insulin is a regulator of energy metabolism and a potent mitogenic agent (Bruce and Corpet, 1996) . High insulin levels may increase the risk of colorectal cancer by stimulating cell proliferation and/or inhibiting apoptosis (Koenuma et al., 1989; Bjork et al., 1993; Wu et al., 1995) . In addition, insulin can increase the bioactivity of insulin-like growth factor-1 by inhibiting the production of insulin-like growth factorbinding proteins (Werner and LeRoith, 1996) . High glucose levels, in theory, could additionally increase the risk of postmenopausal colorectal cancer by exacerbating insulin resistance (Marshall et al., 1991) and conferring a selective growth advantage on malignant cells (Warburg, 1956; Dang and Semenza, 1999) .
To date, a number of studies have examined the association of the metabolic syndrome with risk of colorectal cancer (Trevisan et al., 2001; Colangelo et al., 2002; Ahmed et al., 2006; Bowers et al., 2006; Sturmer et al., 2006; Stocks et al., 2008; Inoue et al., 2009; Jaggers et al., 2009; Pelucchi et al., 2010; Stocks et al., 2010) . These studies differed in their definition of the syndrome and the cut-off values for the individual components, and for the most part have used only baseline measurements to assess the metabolic syndrome. One study (Sturmer et al., 2006) used repeated questionnaire data to assess the metabolic syndrome, and another (Stocks et al., 2010) used repeated measurements on a subset of participants to correct measurements of all patients for random measurement error. Because a single measurement is subject to considerable random error due to imprecision in measurement and short-term and long-term intraindividual variation (Stocks et al., 2010) , use of repeated measurements may improve the characterization of an individual's habitual levels.
We therefore evaluated the association of the metabolic syndrome with risk of postmenopausal colorectal cancer in a subsample of women in the Women's Health Initiative who had repeated measurements of the components of the syndrome during follow-up, thereby permitting assessment of the association longitudinally.
Materials and methods

Study participants
The Women's Health Initiative is a large, multicenter, prospective study of factors affecting the health of postmenopausal women. It includes an observational study (OS, n = 93 676) and three clinical trials (CT, n = 68 132) of hormone therapy, dietary modification, and calcium plus vitamin D supplementation (The Women's Health Initiative Study Group, 1998) . Women were recruited at 40 clinical centers throughout the USA, largely by direct mailings, and were eligible to participate if they were postmenopausal, aged 50-79, likely to reside in their current residence for at least 3 years, and had provided written informed consent. Enrollment took place from 1 October 1993 to 31 December 1998.
The present analysis is based on a 6% random sample of women in the CT (N = 4544) and a 1% sample of women in the OS (N = 1062). All Women's Health Initiative participants had provided a fasting blood sample at baseline. Women in the 6% subsample additionally provided fasting blood samples at years 1, 3, and 6 of follow-up, and women in the 1% sample of women in the OS additionally provided fasting blood samples in year 3 (Howard et al., 2004) . Blood samples were analyzed for glucose, triglycerides, total cholesterol, and high-density lipoprotein cholesterol (HDL-C) (Howard et al., 2004) . In addition, waist circumference, and systolic and diastolic blood pressure were measured by study staff using a standardized protocol at clinical visits. The 6% random sample was stratified by age, clinical center, and hysterectomy status, with oversampling of minority groups to increase the numbers of Black, Hispanic, and Asian-Pacific women.
Case ascertainment
In the CT, cancer outcomes were ascertained through self-administered questionnaires completed every 6 months, and then confirmed by a centralized review of pathology reports, discharge summaries, operative and radiology reports, and tumor registry abstracts. In the OS, outcomes were ascertained annually, and confirmed by the same procedures. After the end of the CT period (2005) , outcomes in all women were identified on an annual basis by mailed questionnaires.
Median follow-up was 11.9 years (range: 0.05-15.4).
Laboratory methods
Fasting blood samples were collected with minimal stasis and maintained at 41C until plasma/serum was separated. Plasma/serum aliquots were then frozen at -801C and sent on dry ice to the central repository (Fisher Bioservices, Rockville, Maryland, USA), where storage at -801C was maintained. Glucose was measured using the hexokinase method on the Hitachi 747 analyzer (Boehringer Mannheim Diagnostics, Indianapolis, Indiana, USA) (Peterson and Young, 1968; Bergmeyer et al., 1974) . An ongoing monthly quality assurance program was maintained with the Diabetes Diagnostic Laboratory at the University of Missouri. Monthly interassay coefficients of variation were less than 2% for mean concentrations of 84 and 301 mg/dl. Total cholesterol and triglycerides were analyzed by enzymatic methods on the Hitachi 747 analyzer (Steiner et al., 1981) . HDL-C was isolated using heparin manganese chloride (Warnick and Albers, 1978) . Coefficients of variation for total cholesterol, triglycerides, and HDL-C were all 2% or less.
Anthropometric measures and blood pressure
Waist circumference at the natural waist or narrowest part of the torso was measured to the nearest 0.1 cm. On each visit, two blood pressure measurements were obtained at least 30 s apart, and the average of the two measurements was used in the analysis. Values for waist circumference and blood pressure in the years corresponding to the blood analytes were used in the analysis.
Definition of the metabolic syndrome
We used the definition of the metabolic syndrome proposed by the Adult Treatment Panel III of the National Cholesterol Education Program (National Heart, Lung, and Blood Institute, 2002; Grundy et al., 2005 ). An indicator variable was created for the presence of the metabolic syndrome (yes/no), defined as having at least three of the following characteristics: waist circumference > 88 cm, fasting glucose Z 100 mg/dl, fasting HDL-C < 50 mg/dl, fasting triglycerides Z 150 mg/dl, and blood pressure Z 130/85 mmHg.
Metabolic syndrome and risk of colorectal cancer Kabat et al. 327 Exclusion of women with diabetes Women who reported taking diabetes medication at baseline or having a baseline fasting serum glucose of at least 126 mg/dl were excluded from the analysis (eight cases and 554 noncases). However, the results were essentially unchanged when women with diabetes were included in the analysis.
After exclusion of women with diabetes and those missing measurements of components of the metabolic syndrome, 81 colorectal cancer cases and 4821 noncases were available for analysis. Of the 81 cases, 65 were in the colon, six in the rectosigmoid junction, and 10 in the rectum.
Statistical analysis
Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the associations between presence of the metabolic syndrome and its components and risk of colorectal cancer, with duration of follow-up (days) as the time scale. For these analyses, study participants were considered to be at risk from their date of enrollment until the date of diagnosis of colorectal cancer, termination of follow-up (30 September 2010), loss to follow-up, withdrawal from the study, or death, whichever occurred first. Event times of participants who had not developed colorectal cancer by the end of follow-up, who had died, or who withdrew from the study before the end of followup were censored.
In the first stage of the analysis, we estimated the risk of colorectal cancer in association with presence of the metabolic syndrome or its individual components at baseline. As indicated above, presence of the metabolic syndrome was defined as having at least three of the individual components and this category was compared with those patients having two or fewer of the individual components. In addition, the individual components of the metabolic syndrome were divided into three categories, using the Adult Treatment Panel III cutoffs for the highest category (lowest for HDL-C), and the median for the remainder of the distribution. Tests for trend were obtained by assigning the median value to each category and modeling this variable as a continuous variable. We also examined the association of 'degree of metabolic syndrome' with risk, using each individual's score, ranging from 0 (reference group) to 5 and obtained by summing scores (1 = present, 0 = absent) for each of the individual components.
We compared the results of a model with age and ethnicity as covariates and a fuller multivariable model. Variables were included in the latter if their addition to the model changed the parameter estimate of the study factors by more than 10%. Variables included in the final model were: age (continuous), ethnicity (white, black, other), BMI (kg/m 2 -continuous), alcohol intake (drinks per week -continuous), physical activity (metabolic equivalent task-h/week -continuous), family history of colorectal cancer (no/yes), participation in the OS versus CT, and treatment arm in each CT. Results of the two models differed little, and we present the fuller multivariable results. All P values are two-sided.
We also repeated the main analysis after excluding patients who were diagnosed with colorectal cancer during the first year of follow-up, in order to reduce the possibility that the presence of preclinical disease affected components of the metabolic syndrome.
In the second stage of the analysis, repeated measurements of the components of the metabolic syndrome were analyzed by modeling them as time-dependent covariates in the Cox proportionate hazards model (Gail, 1981) . With this approach, we evaluated the predictive value of the average of all measurements and measurements obtained in the intervals 1-3 years, 2-4 years, and 3-5 years before diagnosis. In all time-dependent analyses, measurements that were obtained within 1 year of diagnosis were excluded, because these values may have been affected by the presence of subclinical disease.
Results
Cases and noncases were generally similar in terms of background characteristics. However, compared with noncases, cases were older (64.4 vs. 62.5 years, respectively), were more likely to be non-Hispanic white, and had lower levels of physical activity [see (Kabat et al., submitted) for comparison of background characteristics].
The presence of the metabolic syndrome at baseline was associated with increased risk of both colorectal cancer and colon cancer: multivariable-adjusted HRs 2.15, 95% CI 1.30-3.53 and 2.28, 95% CI 1.31-3.98, respectively (Table 1) . (There were too few rectosigmoid or rectal cancer cases for separate analysis of these subsites.) Of the individual components of the metabolic syndrome at baseline, only serum glucose and systolic blood pressure were associated with increased risk. The HR for colorectal cancer among women with a fasting glucose level at least 100 mg/dl, relative to less than 90, was 1.79, 95% CI 0.99-3.24, P = 0.05, and that for colon cancer was 2.22, 95% CI 1.12-4.42, P for trend 0.02. Elevated systolic blood pressure was associated with increased risk of colorectal and colon cancer (HRs 1.82, 95% CI 0.98-3.38, P for trend 0.07), but not colon cancer (HR 1.65, 95% CI 0.86-3.19, for trend 0.12). These associations were unchanged when mutually adjusted. When the number of components of the syndrome was treated as an ordinal variable (relative to the reference group), women with at least four components compared with women with zero components had an HR for colorectal cancer of 1.65, 95% CI 0.74-3.66, P for trend 0.06 and for colon cancer of 2.05, 95% CI 0.83-5.07, P for trend 0.03.
When cases diagnosed within the first year of follow-up were excluded (17 colorectal cancer cases and 13 colon cancer cases), the HRs for the association of the metabolic syndrome (yes/no) with colorectal and colon cancer were: 2.07, 95% CI 1.18-3.63 and 2.25, 95% CI 1.21-4.19, respectively. In time-dependent covariates analyses, presence of the metabolic syndrome was associated with increased risk of colorectal and colon cancer ( Table 2) . HRs were statistically significant for colorectal cancer for the period 2-4 years before diagnosis and were elevated for other time periods. When the averages of all measurements of each component were considered, none of the components showed a significant association, although there was a borderline significant trend for average serum glucose with colorectal and colon cancer (P = 0.11 and 0.09, respectively) (data not shown). 
Discussion
Our results suggest that presence of the metabolic syndrome in postmenopausal women without diabetes is associated with increased risk of colorectal cancer. The majority of the cases included in the study were in the colon, and there were insufficient rectosigmoid or rectal cancer cases to allow separate analyses in these subgroups. The association was largely accounted for by elevated serum glucose and elevated systolic blood pressure, which made independent contributions to risk, whereas waist circumference, serum triglycerides, serum HDL-C, and diastolic blood pressure were not associated with risk. Time-dependent analyses were supportive of results of the baseline analysis.
Previous studies that have examined the association of the metabolic syndrome with risk of colorectal cancer (Trevisan et al., 2001; Colangelo et al., 2002; Ahmed et al., 2006; Bowers et al., 2006; Sturmer et al., 2006; Stocks et al., 2008; Inoue et al., 2009; Jaggers et al., 2009; Pelucchi et al., 2010; Stocks et al., 2010) have reported conflicting results. A number of them reported a positive association of the metabolic syndrome with risk of colorectal cancer (Jaggers et al., 2009; Pelucchi et al., 2010; Stocks et al., 2010) , whereas others did not. Most studies have found associations of only one or two components of the metabolic syndrome with colorectal cancer risk. The most common associations were for serum glucose (Trevisan et al., 2001; Colangelo et al., 2002; Ahmed et al., 2006) and obesity (Bowers et al., 2006; Sturmer et al., 2006; Stocks et al., 2010) .
In addition to studies that examined the association of the metabolic syndrome per se with risk of colorectal cancer (Trevisan et al., 2001; Colangelo et al., 2002; Ahmed et al., 2006; Bowers et al., 2006; Sturmer et al., 2006; Stocks et al., 2008; Inoue et al., 2009; Jaggers et al., 2009; Pelucchi et al., 2010; Stocks et al., 2010) , other studies have focused on the association of individual components of the syndrome with risk of colorectal cancer, some of which have received more study than others. Increased central adiposity (as measured by waist circumference and/or waist-hip ratio) has been associated with increased risk of colorectal cancer in most cohort studies and metaanalyses (Schoen et al., 1999; Larsson and Wolk, 2007; Moghaddam et al., 2007; Wang et al., 2008; Ning et al., 2010; Oxentenko et al., 2010; Park et al., 2011) . Findings regarding dyslipidemia, including total cholesterol (Tornberg et al., 1986; Schatzkin et al., 1988; Jarvinen et al., 2001) and triglycerides (Tsushima et al., 2005; van Duijnhoven et al., 2011) have been inconsistent or null. Few studies have examined HDL cholesterol in relation to colorectal cancer risk, but a recent study showed an inverse association (van Duijnhoven et al., 2011) .
In several studies, hypertension has been linked to higher colorectal cancer risk (Palmqvist et al., 2003; Ahmed et al., 2006; Stocks et al., 2008) , but no association was found in other studies (Bowers et al., 2006; Sturmer et al., 2006) . Of five studies that examined insulin levels (Schoen et al., 1999; Tsushima et al., 2005; Limburg et al., 2006; Gunter et al., 2008; Van Duijnhoven et al., 2011) , only one reported evidence of a positive association (Schoen et al., 1999) after adjustment for covariates. Of eight studies that examined blood glucose levels in relation to colorectal cancer risk (Yamada et al., 1998; Schoen et al., 1999; Nilsen and Vatten, 2001; Trevisan et al., 2001; Jee et al., 2005; Tsushima et al., 2005; Limburg et al., 2006; Gunter et al., 2008) , one found a weak positive association (with in-situ carcinoma) (Yamada et al., 1998) , two reported significant positive associations with colorectal cancer (Schoen et al., 1999; Trevisan et al., 2001) , two reported a significant association in one sex but not in the other (Nilsen and Vatten, 2001; Jee et al., 2005) , and three studies found no association (Tsushima et al., 2005; Limburg et al., 2006; Gunter et al., 2008) .
The literature on the metabolic syndrome and colorectal cancer suffers from the difficulty of teasing apart a large number of highly correlated behavioral (elevated BMI, abdominal adiposity, low physical activity, and an energyrich diet) and metabolic factors (diabetes, hyperinsulinemia, hyperglycemia, hypertriglyceridemia, high blood pressure, and dyslipidemia). In the present study, the HRs for the full multivariable model presented in Table 1 did not differ from those adjusted for age and ethnicity, indicating that our results were not confounded by such factors as BMI or physical activity. Furthermore, the associations of baseline glucose level and systolic blood pressure were unchanged when mutually adjusted, suggesting that they make independent contributions to risk. Other components of the metabolic syndrome, including waist circumference, serum HDL-cholesterol, serum triglycerides, and diastolic blood pressure, showed no association with colorectal cancer. In an analysis of the associations of insulin and glucose levels in this dataset Most recent measurement within the time interval was used to predict presence of the metabolic syndrome. (Kabat et al., submitted) , we reported the positive association of glucose with colorectal cancer, whereas insulin levels showed no association with risk. Most previous studies examining the metabolic syndrome in relation to colorectal cancer risk included patients with diabetes (Trevisan et al., 2001; Ahmed et al., 2006; Sturmer et al., 2006; Stocks et al., 2008; Pelucchi et al., 2010) , whereas we excluded women with confirmed diabetes at baseline. However, their inclusion in alternative analyses did not alter the results.
Our results and those of a number of other studies suggest that the association of the metabolic syndrome with colorectal cancer may be driven by several of the individual components rather than by the syndrome per se. Furthermore, it is unclear what mechanism underlies the associations of specific components with risk, such as serum glucose and obesity. Our results regarding glucose are consistent with those of a number of other studies (Schoen et al., 1999; Trevisan et al., 2001; Colangelo et al., 2002; Ahmed et al., 2006; Stocks et al., 2008) and suggest that hyperglycemia and resulting hyperinsulinemia in particular may play a causative role in colorectal carcinogenesis.
The present study benefited from the availability of clinical measurement data collected at baseline and at scheduled intervals throughout follow-up on a subset of the Women's Health Initiative cohort. Additional strengths include the centralized adjudication of colorectal cancer, the high degree of completeness of followup, and the availability of information on risk factors for colorectal cancer. Moreover, we excluded diabetics from the analysis, because we were interested in whether insulin resistance is associated with increased risk of colorectal cancer.
The major limitation of this study is the small number of cases that limited our ability to assess the metabolic syndrome in subgroups (particularly rectal cancer) and among women who were not in any intervention group in the CT. Nevertheless, the observed associations of serum glucose and systolic blood pressure with risk of colon and colorectal cancer appeared to be robust and to be unaffected when treatment arm of the CTs and other potential confounding variables were included in the Cox models. Regarding the time-dependent covariates analysis, except for the average of measurements of the individual components, the number of cases was reduced by approximately 50%, and for this reason, the analyses should be considered exploratory. Nevertheless, presence of the metabolic syndrome per se at various intervals preceding diagnosis was associated with increased risk.
In summary, we found a positive association of the metabolic syndrome with risk of colorectal and colon cancer, which was largely accounted for by serum glucose levels and systolic blood pressure. The biological mechanism underlying these associations remains to be clarified.
